- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02088710
Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The majority of breast cancer patients discontinues today's standard adjuvant treatment (endocrine therapy) due to side effects and reduced quality of life. Thereby, most side effects are unspecific, suggesting a role of psychological factors as patients´ expectations (nocebo effects). Moreover, patients are not informed sufficiently about their treatment.
Using a longitudinal design, the nature and onset of adverse side effects and their association to treatment related expectations are investigated. Postoperative patients with hormone receptor-positive breast cancer are assessed before the start of adjuvant treatment. All patients receive standardized, additional information about endocrine therapy. Expectations about side effects, knowledge and satisfaction with the enhanced information are assessed before and after informing patients. Side effects, quality of life and adherence are measured three months, two and five years after start of medication intake.
It will be analyzed if patients' response expectations predict side effects and quality of life during medication intake to provide insights into pathways of clinical nocebo effects. Further, this study examines the effects of a structured treatment information on patients' satisfaction with information, response expectations, knowledge and adherence. The study findings promise significant advances in the clinical nocebo research with strong implications for clinical and research practice.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hessen
-
Marburg, Hessen, Germany, 35032
- Philipps University Marburg Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Post surgery women with estrogen receptor positive breast cancer scheduled to start first-line adjuvant endocrine therapy with Tamoxifen (+/- GnRH) or a third generation Aromatase inhibitor at the Breast Cancer Centre
- Sufficient knowledge of German language and ability to give informed consent
- Age of 18 and more
Exclusion Criteria:
- Presence of a serious comorbid psychiatric condition (schizophrenia or addiction, severe depression or anxiety)
- Presence of a life threatening comorbid medical condition
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Side Effects
Time Frame: up to 5 years
|
General Assessment of Side Effects (GASE)
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life
Time Frame: up to 5 years
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with breast module (QLQ-BR23)
|
up to 5 years
|
Adherence
Time Frame: up to 5 years
|
Medication Adherence Report Scale (MARS-D); Adherence with endocrine treatment; reasons for non-adherence
|
up to 5 years
|
Knowledge
Time Frame: up to 5 years
|
Patients' knowledge of hormone receptor status of their tumor
|
up to 5 years
|
Satisfaction with Information
Time Frame: Baseline
|
Satisfaction with Information about Medicines Scale, (SIMS-D)
|
Baseline
|
Expectations
Time Frame: Baseline
|
General Assessment of Side Effects Scale - Expectations Module
|
Baseline
|
Coping with Side Effects
Time Frame: Follow-up (3 months, 2 years, 5 years)
|
General Assessment of Side Effects Scale -Coping Module
|
Follow-up (3 months, 2 years, 5 years)
|
Collaborators and Investigators
Investigators
- Study Chair: Winfried Rief, Prof. Dr., Philipps University Marburg Medical Center
Publications and helpful links
General Publications
- Pan Y, Heisig SR, von Blanckenburg P, Albert US, Hadji P, Rief W, Nestoriuc Y. Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. Breast Cancer Res Treat. 2018 Apr;168(3):667-677. doi: 10.1007/s10549-017-4637-2. Epub 2018 Jan 12.
- Nestoriuc Y, von Blanckenburg P, Schuricht F, Barsky AJ, Hadji P, Albert US, Rief W. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016 Oct;27(10):1909-15. doi: 10.1093/annonc/mdw266. Epub 2016 Aug 22.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BB-2011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Breast Cancer
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Institut fuer FrauengesundheitSamsung Bioepis Co., Ltd.RecruitingBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer FemaleGermany
-
Wake Forest University Health SciencesAtrium Health NavicentActive, not recruitingBreast Cancer Female | Early-stage Breast CancerUnited States
Clinical Trials on Enhanced information about endocrine therapy
-
National University of SingaporeActive, not recruitingAnxiety | Educational Problems | Marriage Age | Childbearing, Delayed | Age Related Female InfertilitySingapore
-
University of CopenhagenUnknown
-
Hospital San Carlos, MadridCompleted
-
University of MichiganNational Institute of Allergy and Infectious Diseases (NIAID); Shanghai Municipal...Terminated
-
Celal Bayar UniversityManisa Celal Bayar UniversityCompletedBreastfeeding | Breastfeeding, ExclusiveTurkey
-
Ottawa Hospital Research InstituteRecruiting
-
Ludwig-Maximilians - University of MunichProf. OTTO Beisheim Stiftung (Germany)CompletedDepressive Disorder | Depression in AdolescenceGermany
-
Ludwig-Maximilians - University of MunichProf. OTTO Beisheim Stiftung (Germany)CompletedDepressive Disorder | Depression in AdolescenceGermany
-
Radboud University Medical CenterUMC Utrecht; St. Antonius Hospital; The Netherlands Cancer Institute; Franciscus... and other collaboratorsCompletedBreast Cancer | Cognitive Decline | Cognitive Symptoms
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruitingUmbilical Artery Embolism,Single Umbilical Artery,Pregnancy OutcomeChina